UNLABELLED: Dendritic cells (DCs) capture and process proteins and present peptides on the cell surface in the context of major histocompatibility complex I and II molecules to induce antigen-specific T cell immune responses. The aims of this study were to (1) employ an expanded and purified DC population and load them with aspartate-β-hydroxylase (ASPH), a highly expressed tumor-associated cell surface protein, and (2) to determine if immunization induced antitumor effects in an orthotopic rat model of intrahepatic cholangiocarcinoma. Splenocytes were incubated with ASPH-coated beads and passed through a magnetic field to yield an 80% pure DC OX62+ population. This DC subset was stimulated with granulocyte-macrophage colony-stimulating factor, interleukin-4, CD40L, and interferon-γ, resulting in a 40-fold increase in interleukin-12A messenger RNA expression to subsequently generate a T helper 1-type immune response. After incubation with the cytokine cocktail, DCs were found to have matured, as demonstrated by increased expression of CD40, CD80, and CD86 costimulatory molecules. Immunization with ASPH-loaded DCs induced antigen-specific immunity. A clone of the parental tumorigenic rat BDEneu cholangiocyte cell line, designated BDEneu-CL24, was found to have the highest number of cells expressing this surface protein (97%); it maintained the same phenotypic characteristics of the parental cell line and was used to produce intrahepatic tumors in immunocompetent syngeneic Fisher-344 rats. Immunization with ASPH-loaded DCs generated cytotoxicity against cholangiocarcinoma cells in vitro and significantly suppressed intrahepatic tumor growth and metastasis, and was associated with increased CD3+ lymphocyte infiltration into the tumors. CONCLUSION: These findings suggest that immunization with ASPH-loaded DCs may constitute a novel therapeutic approach for intrahepatic cholangiocarcinoma, because this protein also appears to be highly conserved and expressed on human hepatobiliary tumors.
UNLABELLED: Dendritic cells (DCs) capture and process proteins and present peptides on the cell surface in the context of major histocompatibility complex I and II molecules to induce antigen-specific T cell immune responses. The aims of this study were to (1) employ an expanded and purified DC population and load them with aspartate-β-hydroxylase (ASPH), a highly expressed tumor-associated cell surface protein, and (2) to determine if immunization induced antitumor effects in an orthotopic rat model of intrahepatic cholangiocarcinoma. Splenocytes were incubated with ASPH-coated beads and passed through a magnetic field to yield an 80% pure DC OX62+ population. This DC subset was stimulated with granulocyte-macrophage colony-stimulating factor, interleukin-4, CD40L, and interferon-γ, resulting in a 40-fold increase in interleukin-12A messenger RNA expression to subsequently generate a T helper 1-type immune response. After incubation with the cytokine cocktail, DCs were found to have matured, as demonstrated by increased expression of CD40, CD80, and CD86 costimulatory molecules. Immunization with ASPH-loaded DCs induced antigen-specific immunity. A clone of the parental tumorigenic rat BDEneu cholangiocyte cell line, designated BDEneu-CL24, was found to have the highest number of cells expressing this surface protein (97%); it maintained the same phenotypic characteristics of the parental cell line and was used to produce intrahepatic tumors in immunocompetent syngeneic Fisher-344 rats. Immunization with ASPH-loaded DCs generated cytotoxicity against cholangiocarcinoma cells in vitro and significantly suppressed intrahepatic tumor growth and metastasis, and was associated with increased CD3+ lymphocyte infiltration into the tumors. CONCLUSION: These findings suggest that immunization with ASPH-loaded DCs may constitute a novel therapeutic approach for intrahepatic cholangiocarcinoma, because this protein also appears to be highly conserved and expressed on humanhepatobiliary tumors.
Authors: Giorgio Ercolani; Gaetano Vetrone; Gian Luca Grazi; Osamu Aramaki; Matteo Cescon; Matteo Ravaioli; Carla Serra; Giovanni Brandi; Antonio Daniele Pinna Journal: Ann Surg Date: 2010-07 Impact factor: 12.969
Authors: Joseph E Dinchuk; Richard J Focht; Jennifer A Kelley; Nancy L Henderson; Nina I Zolotarjova; Richard Wynn; Nicola T Neff; John Link; Reid M Huber; Timothy C Burn; Mark J Rupar; Mark R Cunningham; Bernard H Selling; Jianhong Ma; Andrew A Stern; Gregory F Hollis; Robert B Stein; Paul A Friedman Journal: J Biol Chem Date: 2001-12-31 Impact factor: 5.157
Authors: Takashi Maeda; Paul Sepe; Stephanie Lahousse; Seishu Tamaki; Munetomo Enjoji; Jack R Wands; Suzanne M de la Monte Journal: J Hepatol Date: 2003-05 Impact factor: 25.083
Authors: Kevin S Palumbo; Jack R Wands; Howard Safran; Thomas King; Rolf I Carlson; Suzanne M de la Monte Journal: Pancreas Date: 2002-07 Impact factor: 3.327
Authors: Paul S Sepe; Stephanie A Lahousse; Brad Gemelli; Howard Chang; Takashi Maeda; Jack R Wands; Suzanne M de la Monte Journal: Lab Invest Date: 2002-07 Impact factor: 5.662
Authors: Katsuya Nagaoka; Xuewei Bai; Kosuke Ogawa; Xiaoqun Dong; Songhua Zhang; Yanmei Zhou; Rolf I Carlson; Zhi-Gang Jiang; Steve Fuller; Michael S Lebowitz; Hossein Ghanbari; Jack R Wands Journal: Cancer Lett Date: 2019-02-12 Impact factor: 8.679
Authors: Yoshito Tomimaru; Sasmita Mishra; Howard Safran; Kevin P Charpentier; William Martin; Anne S De Groot; Stephen H Gregory; Jack R Wands Journal: Vaccine Date: 2015-01-25 Impact factor: 3.641
Authors: Lennart Brewitz; Anthony Tumber; Inga Pfeffer; Michael A McDonough; Christopher J Schofield Journal: Sci Rep Date: 2020-05-26 Impact factor: 4.379
Authors: Inga Hochnadel; Uta Kossatz-Boehlert; Nils Jedicke; Henrike Lenzen; Michael P Manns; Tetyana Yevsa Journal: Hum Vaccin Immunother Date: 2017-11-07 Impact factor: 3.452